2026
05 Jan
Protalix BioTherapeutics Letter to Stockholders

CARMIEL, Israel , Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharm

2025
17 Dec
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator ®

2025
13 Nov
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

Company to host conference call and webcast today at 8:00 a.m. EST CARMIEL, Israel , Nov. 13, 2025 /PRNewswire